Erratum to: Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease (Eur J Heart Fail, (2016), 18, (28-37), 10.1002/ejhf.444);Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

European Journal of Heart Failure

Volumn 18, Issue 1, 2016, Pages 28-37

  Bramlage, Peter ^a,b   Swift, Stephanie L ^a   Thoenes, Martin ^c   Minguet, Joan ^a   Ferrero, Carmen ^b   Schmieder, Roland E ^d  

^a Institute for Pharmacology and Preventive Medicine   (Germany)

^b UNIVERSITY OF SEVILLE   (Spain)

^c Leman Research Institute   (Switzerland)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Antagonist; ARTS; BAY 94 8862; Disease; Failure; Finerenone; Heart; Kidney; Mineralocorticoid; Receptor

Indexed keywords

BR 4628; DIHYDROPYRIDINE; EPLERENONE; FINERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PF 03882845; PLACEBO; POTASSIUM; PYRAZOLINE DERIVATIVE; SM 368229; SPIRONOLACTONE; UNCLASSIFIED DRUG; NAPHTHYRIDINE DERIVATIVE;

AMENORRHEA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SINGLE DRUG DOSE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; ELECTROLYTE BALANCE; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 84954098940     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.888     Document Type: Erratum

References (65)

1. Remuzzi G, Perico N, Macia M, Ruggenenti P,. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 99: S57-S65.
2. Funder JW,. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009; 53: 286-290.
3. Connell JM, Davies E,. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
4. Messaoudi S, Azibani F, Delcayre C, Jaisser F,. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012; 350: 266-272.
5. Zannad F., Aldosterone and heart failure. Eur Heart J 1995; 16 Suppl N: 98-102.
6. Mihailidou AS, Loan Le TY, Mardini M, Funder JW,. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312.
7. Deo R, Yang W, Khan AM, Bansal N, Zhang X, Leonard MB, Keane MG, Soliman EZ, Steigerwalt S, Townsend RR, Shlipak MG, Feldman HI,. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 2014; 64: 103-110.
8. Funder JW,. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005; 93: 121-125.
9. Fuller PJ, Yao Y, Yang J, Young MJ,. Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol 2012; 213: 15-24.
10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
11. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M,. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
12. Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA,. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013; 6: 166-173.
13. Hu LJ, Chen YQ, Deng SB, Du JL, She Q,. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 75: 1202-1212.
14. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G,. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009; 11: 68-76.
15. van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, Maggioni AP, Voors AA,. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103-111.
16. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF,. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4:CD007004.
17. Batterink J, Stabler SN, Tejani AM, Fowkes CT,. Spironolactone for hypertension. Cochrane Database Syst Rev 2010; 8:CD008169.
18. Weinberger MH, Roniker B, Krause SL, Weiss RJ,. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716.
19. Parthasarathy HK, Menard J, White WB, Young WF, Jr., Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM,. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-990.
20. Mantero F, Lucarelli G,. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61: 52-60.
21. Grandi AM, Imperiale D, Santillo R, Barlocco E, Bertolini A, Guasti L, Venco A,. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-652.
22. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
23. Samuel JL, Delcayre C,. Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 2010; 7: 125-127.
24. Kolkhof P, Borden SA,. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012; 350: 310-317.
25. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
26. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA,. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
27. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D,. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10: 297-303.
28. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R,. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-1650.
29. Schepkens H, Vanholder R, Billiouw JM, Lameire N,. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438-441.
30. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH,. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147-149.
31. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC,. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156-1162.
32. Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B,. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585-1593.
33. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP,. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-123.
34. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X,. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 2005; 19: 1460-1473.
35. Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F., Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014; 7: 51-58.
36. Bauersachs J., The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J 2013; 34: 2426-2428.
37. Ergueden J-K, Kolkhof P, Kuhl A, Pook E, Sandner P, Schlemmer K-H, Stasch J-P,. Fluorenone 1, 4,-Dihydropyridin Derivatives. Germany: Bayer Healthcare AG; 2005.
38. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, Nitsche A, Erguden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P,. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012; 7: 13851-403.
39. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P,. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285: 29932-29940.
40. Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, Collins JT, Blinn JR, Numann RE, Hu X, Huang HC,. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010; 53: 4300-4304.
41. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X,. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-748.
42. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L, Eitner F, Albrecht-Kupper B, Schafer S,. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64: 69-78.
43. Lentini S, Kimmeskamp-Kirschbaum N, Wensing G, Heinig R,. BAY 94-8862 exerts a potent natriuretic effect in healthy male subjects pre-treated with fludrocortisone: findings from a proof-of-concept study. Circulation 2012; 126:A10732.
44. Sica DA,. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-29.
45. Garcia NH, Baigorria ST, Juncos LI,. Hyperkalemia, renal failure, and converting-enzyme inhibition: an overrated connection. Hypertension 2001; 38: 639-644.
46. Kolkhof P, Kretschmer A, Barfacker L, Hartmann E, Schafer S,. Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist. Eur Heart J 2012; 33 (suppl 1): 978-979.
47. Schupp N, Kolkhof P, Queisser N, Bärfacker L, Kretschmer A, Hartmann E, Schäfer S, Stopper H,. Aldosterone causes DNA damage in vitro and in kidneys of DOCA/salt rats, mediated by the mineralocorticoid receptor. Toxicol Lett 2009; 189S: S98.
48. Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM,. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med 2011; 9: 180.
49. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F,. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012; 14: 668-675.
50. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F,. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34: 2453-2463.
51. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K,. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-2918.
52. Ruilope LM, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Ferreira AC, Pieper A, Kimmeskamp-Kirschbaum N, Bakris GL,. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 2014; 40: 572-581.
53. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM,. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015; 314: 884-894.
54. Pitt B, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G,. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail 2015; 17: 224-232.
55. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B,. Results of ARTS-HF: finerenone versus eplerenone in patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. 2015. Available at: http://www.escardio.org/static-file/Escardio/Press-media/Press%20releases/2015/Congress/ARTS-HF-Filippatos.pdf (4 November 2015).
56. Menard J., The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52.
57. Yang J, Young MJ,. The mineralocorticoid receptor and its coregulators. J Mol Endocrinol 2009; 43: 53-64.
58. Tamargo J, Solini A, Ruilope LM,. Comparison of agents that affect aldosterone action. Semin Nephrol 2014; 34: 285-306.
59. Levy DG, Rocha R, Funder JW,. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740.
60. Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B,. Updated national and international hypertension guidelines: a review of current recommendations. Drugs 2014; 74: 2033-2051.
61. Schupp N, Kolkhof P, Queisser N, Gartner S, Schmid U, Kretschmer A, Hartmann E, Oli RG, Schafer S, Stopper H,. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 2011; 25: 968-978.
62. Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K,. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na + excretion activity. J Pharmacol Sci 2011; 115: 346-353.
63. Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K,. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats. Pharmacology 2012; 89: 44-52.
64. Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW, Rico JR, Garland DJ, Blinn JR, Collins JT, Yang S, Huang HC, McGee KF, Wendling JM, Dietz JD, Payne MA, Homer BL, Heron MI, Reitz DB, Hu X,. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010; 53: 5979-6002.
65. Orena S, Maurer TS, She L, Eudy R, Bernardo V, Dash D, Loria P, Banker ME, Tugnait M, Okerberg CV, Qian J, Boustany-Kari CM,. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol 2013; 4: 115.